Revenue from Contracts with Customers - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Disaggregation Of Revenue [Line Items]
Contract assets						$ 8,929
Contract liabilities	$ 5,668			$ 5,668		10,701
Royalty revenue	617,397		$ 276,219	904,992	$ 554,764
Janssen Pharmaceutica N.V.
Disaggregation Of Revenue [Line Items]
Royalty revenue related to back royalties	195,400			195,400
Back royalties late payment interest				8,100
Contract liabilities–short-term
Disaggregation Of Revenue [Line Items]
Contract liabilities	3,300			3,300		6,800
Other long-term liabilities
Disaggregation Of Revenue [Line Items]
Contract liabilities	2,400			2,400		$ 3,900
Royalty
Disaggregation Of Revenue [Line Items]
Royalty revenue	354,015		59,752	388,437	126,095
Royalty | VUMERITY
Disaggregation Of Revenue [Line Items]
Royalty revenue	21,926		20,520	38,151	39,720
Royalty | Long-Acting INVEGA Products
Disaggregation Of Revenue [Line Items]
Royalty revenue	321,239		$ 26,648	$ 334,801	$ 63,702
US Based Royalties | Long-Acting INVEGA Products
Disaggregation Of Revenue [Line Items]
Royalty revenue		$ 50,200
Worldwide Based Royalties | Long-Acting INVEGA Products
Disaggregation Of Revenue [Line Items]
Royalty revenue	$ 75,700
Minimum
Disaggregation Of Revenue [Line Items]
Manufacturing Process period				10 days
Maximum
Disaggregation Of Revenue [Line Items]
Manufacturing Process period				56 days